




an Open Access Journal by MDPI

Impact Factor 1.0

CiteScore 2.3

COVID



[mdpi.com/
journal/
covid](https://mdpi.com/journal/covid)



Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *COVID*. *COVID* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. With the efforts of our professional team and the great potential of *COVID* topics, the impact factor of this journal will dramatically increase in the coming years. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Giuseppe Novelli

Aims

COVID (ISSN 2673-8112) is an open access journal that provides an advanced and multidisciplinary forum for the study of coronaviruses, coronavirus-related diseases and global impact. Our aim is to publish papers on all aspects of coronaviruses, from basic molecular and clinical research to COVID-related public health studies, physical and psychological health, economic and environmental impact and all other aspects affected by coronaviruses.

We welcome the submission of original research articles, reviews that are not part of Special Issues, communications, brief reports and several other types of papers. We encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced. Large electronic files, software, movies, etc., that cannot be published in the main paper can be posted as supplementary material.

Scope

- **Human or Animal Coronaviruses:** epidemiology and evolution; viral cross-species transmission and evolution; viral host interactions; mechanistic studies on coronaviruses; and pre-clinical studies on cellular and animal models.
- **Clinical Treatment:** viral respiratory infection; coronavirus pneumonia; severe acute respiratory syndrome; Middle East respiratory syndrome; and coronavirus immunity.
- **Treatment Development:** vaccine design; therapeutic vaccines; antiviral drug design; monoclonal antibodies; peptides; assay development and test kits; diagnostics; combinatorial therapies; and advances in cell as well as gene therapies.
- **Public Health:** pandemic surveillance; epidemiologic models; dynamic models; social and physical effects of lockdowns; mental health; vaccination campaigns; pandemic-related retrospective studies; and work engagement.
- **Healthcare and COVID Complications:** ventilation and transmission; acute respiratory failure; pneumonia; acute respiratory distress syndrome; acute liver injury; acute cardiac injury; cardiovascular risk factors; secondary infection; acute kidney injury; septic shock; comorbidities; and nursing perspectives.
- **Global Impact:** economic impact; lifestyle changes; online education; tourism; environmental impact; food supply; and logistics.
- **Host Genetics and Susceptibility/Resistance:** epidemiological and experimental evidence; predisposition; monogenic and polygenic inheritance; errors of immunity; and interferonopathies.

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Journal Rank

CiteScore - Q2 (Immunology and Microbiology (miscellaneous))

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Coverage by Leading Indexing Services

ESCI (Web of Science), Scopus, CAPlus / SciFinder, and other databases.

Rapid Publication

A first decision is provided to authors approximately 20.6 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2025)

MDPI is a member of

CASPA



STM¹



SPARC*
Europe



DOAJ



ORCID



Editorial Office

covid@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

[mdpi.com](https://www.mdpi.com)

July 2025

